CEBPA and acute myeloid leukemia: Although CEBPA mutations are widely investigated in numerous studies and several reviews have already been published to discuss their molecular mechanisms and clinical relevance (3–7), newly emerging evidence makes it necessary to reconsider the pathogenesis, subsets, and treatment choice of AML with CEBPA mutations.